Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Catalent Talks Cost-Cutting in Biologic Drug Manufacturing | Contract Pharma

What are you searching for?

Sign in
Videos

Catalent Talks Cost-Cutting in Biologic Drug Manufacturing

Steve Perry, PE, Sr. Director, Manufacturing Sciences, Catalent Biologics shares insight

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma



The “Meeting Bioprocessing Manufacturing Capacity Demands” panel session at Interphex 2019 focused on solutions for efficient and cost-effective biologic drug manufacturing.
 
The panelists included:
 Michael Felo, Director, Downstream Process Integration, Next Generation Processing, MilliporeSigma
 Eric S Langer, President and Managing Partner, BioPlan Associates, Inc.
 Rick Morris, Senior Vice President R&D, Pall Biotech, Pall Corporation
 Steve Perry, Senior Director, Manufacturing Sciences, Catalent Biologics
 Brady Cole, Vice President, Applications, ABEC
 Madhu Raghunathan, Product Strategy Leader – BioProcess Hardware, GE Healthcare Life Sciences
 
The discussion took place on April 3, 11:00 a.m. – noon, innovation stage, #1281. One of the participants, Steve Perry of Catalent Biologics, spoke with Contract Pharma to share the company’s thoughts on cost cutting within the biologic manufacturing space, along with industry trends that companies must keep up with to be successful.
 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics